Analysis after 4 weeks of treatment showed significantly higher levels of peripheral blood T cells as compared to the controls, further demonstrating the selective binding of m909 CAR T cells to FRβ.11 Thus, this innovative development of anti-FRβ m909 CAR T cells therapy presents a promising platform for the treatment of autoimmune diseases and AML. The gene discussed is FOLR2; the disease is acute myeloid leukemia.